ACOR Financial Facts
Cost of sales: 27.64MNet loss per share-basic (earnings per share): -0.28
See Full Income Statement
Accumulated other comprehensive income: -3.62M
Total assets: 1.32B
See Full Balance Sheet
Acorda Therapeutics, Inc. (ACOR) Earnings
|
Expand Research on ACOR
Next EPS Date | N/A | EPS Growth Rate | -139.7% *Last Qtr. |
---|---|---|---|
Average EPS % Beat Rate | -188.2% | Revenue Growth Rate | +63.1% *Last Qtr. |
Average % Move 1-Wk after EPS | -8.4% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
8/8/23 | Q223 | -$7.55 | N/A | N/A | $29.68M | N/A | N/A | Details | |||
8/4/22 | Q222 | -$3.15 | -$0.36 | -$2.79 | $18.2M | $29.1M | N/A | Details | |||
3/4/21 | Q420 | -$2.50 | -$1.48 | -$1.02 | $38.16M | $34M | N/A | Details | |||
5/6/21 | Q121 | -$2.46 | -$2.54 | +$0.08 | $28.86M | $22.15M | N/A | Details | |||
8/5/21 | Q221 | -$1.87 | -$2.09 | +$0.22 | $31.78M | $29.94M | N/A | Details | |||
11/9/21 | Q321 | -$1.43 | -$1.56 | +$0.13 | $31.45M | $30.57M | N/A | Details | |||
5/11/23 | Q123 | -$0.69 | N/A | N/A | $22.25M | N/A | N/A | Details | |||
3/9/22 | Q421 | -$0.67 | N/A | N/A | $36.97M | $31.01M | N/A | Details |